Jennifer Doudna

Jennifer A. Doudna is an American biochemist and professor at the University of California, Berkeley, where she holds the Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences. She is also a senior investigator at the Gladstone Institutes and a founder of the Innovative Genomics Institute. Her research with Emmanuelle Charpentier helped establish CRISPR-Cas9 as a programmable genome-editing technology. For this work, they received the 2020 Nobel Prize in Chemistry. Doudna’s work has influenced genetic medicine, biotechnology, and research on gene function and disease.

Jennifer Doudna is an **American biochemist** best known for co-developing **CRISPR-Cas9**, the genome-editing technology that allows DNA to be cut and modified with high precision.[1][6][13] She was born in **1964** and is a professor at **UC Berkeley** and a faculty scientist at **Lawrence Berkeley National Laboratory**; Berkeley also lists her as holding the **Li Ka Shing Chancellor’s Chair** in biomedical and health sciences.[1][3] Her most notable work was the 2012 discovery, with **Emmanuelle Charpentier**, that CRISPR-Cas9 could be programmed as a general-purpose gene-editing tool, which became the basis for modern genome editing.[1][4][11] For that work, Doudna and Charpentier shared the **2020 Nobel Prize in Chemistry**.[1][6][13] She also founded the **Innovative Genomics Institute** in 2014 to advance CRISPR applications in human health, agriculture, and climate-related research.[7][10]

# Jennifer Doudna Jennifer Doudna is a biochemist and molecular biologist known for her foundational work on CRISPR gene-editing technology. **Background:** - Earned her Ph.D. in biochemistry from Harvard University - Trained as a structural biologist **Current Role:** - Professor of Chemistry and Molecular and Cell Biology at UC Berkeley - Co-director of the Innovative Genomics Institute at Berkeley **Notable Work:** - Co-developed CRISPR-Cas9 gene editing with Emmanuelle Charpentier (published 2012) - Their work demonstrated how to use the bacterial immune system as a precise tool for editing DNA - Awarded the Nobel Prize in Chemistry in 2020 (shared with Charpentier) for this discovery **Other Recognition:** - Her work has been foundational to modern biotechnology and has applications in treating genetic diseases, cancer, and other conditions - She has also been vocal about ethical considerations in gene editing, particularly regarding germline editing This summary reflects her major contributions to science as of my last training data.

**Jennifer Doudna** is an American biochemist renowned for her pioneering work in genome editing. * **Background:** Born in Washington, D.C., in 1964, Doudna earned her B.A. in biochemistry from Pomona College in 1985 and her Ph.D. in biological chemistry and molecular pharmacology from Harvard University in 1989. She completed her postdoctoral research at the University of Colorado Boulder under Nobel laureate Thomas Cech. * **Current Role:** She is a professor of chemistry, and of molecular and cell biology at the University of California, Berkeley. She also serves as the chair of the Innovative Genomics Institute, the president of the Gladstone-UCSF Institute of Genomic Immunology, and holds investigator positions at the Howard Hughes Medical Institute and the Innovative Genomics Institute. * **Notable Work:** Doudna is best known for her fundamental research on CRISPR-Cas9 genome editing. In 2012, alongside Emmanuelle Charpentier, she co-led the breakthrough discovery that CRISPR-Cas9 could be used to reprogram and precisely cut DNA, transforming it into an accessible tool for gene editing. For this achievement, Doudna and Charpentier were jointly awarded the Nobel Prize in Chemistry in 2020.

Jennifer Doudna is an American biochemist renowned for her contributions to genome editing. **Background**: Born in 1964, she earned a PhD in biochemistry from Harvard University in 1989 and conducted postdoctoral research at the University of Colorado Boulder and Yale University. **Current role**: She is a professor of chemistry and molecular and cell biology at the University of California, Berkeley, and serves as executive director of the Innovative Genomics Institute. **Notable work**: In 2012, she co-developed CRISPR-Cas9 as a precise gene-editing tool with Emmanuelle Charpentier, enabling targeted DNA modifications; they shared the 2020 Nobel Prize in Chemistry for this discovery, which has transformed genetic research, medicine, and biotechnology.